Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Oct;13(10):783-4.
doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.

Spironolactone revisited

Stergios A Polyzos, Jannis Kountouras, Christos Zavos, Georgia Deretzi
Comment

Spironolactone revisited

Stergios A Polyzos et al. J Clin Hypertens (Greenwich). 2011 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Costa MB, Andrade Ezequiel DG, Morais Lovis JC, et al. Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome. J Clin Hypertens (Greenwich). 2010;12:753–755. - PMC - PubMed
    1. Polyzos SA, Kountouras J, Zafeiriadou E, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst. 2011;Epub ahead of print (DOI: 10.1177/1470320311402110). - DOI - PubMed
    1. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;72:299–314. - PubMed
    1. Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high‐fat and high‐fructose diet. Endocrinology. 2010;151:2040–2049. - PubMed
    1. Yutaka M, Mifune M, Kubota E, et al. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin‐converting enzyme inhibitor or an angiotensin type 1 receptor blocker. Clin Exp Hypertens. 2009;31:648–656. - PubMed

Substances